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    Diseases caused by parasitic nematodes are serious public health problems in 
developing countries that affect millions of people worldwide. Treatments for 
parasitic nematode caused diseases, such as the lymphatic filariasis caused by Brugia 
malayi, have not been well developed to date. The enzyme Cofactor-independent 
phosphoglycerate mutase (iPGM) catalyzes the critical interconversion of 
2-phosphoglycerate and 3-phosphoglycerate in the glycolytic and gluconeogenic 
metabolic pathways that are essential for the growth of nematodes, implicating iPGM 
as a potential drug target. However, iPGM is considered as protein with low 
“druggability”, and is thus not suitable for targeting with conventional small 
molecules. Since small molecules do not have sufficient binding interfaces to interact 
with the target proteins. Thus, alternative approaches are required for the discovery of 
iPGM inhibitors, which may be useful in the development of anti-parasite therapies. 
In this thesis, I report the discovery of macrocyclic peptide inhibitors against iPGMs 
via the Random non-standard Peptide Integrated Discovery (RaPID) system, Such an 
approach enables the rapid selection of high affinity iPGM-binders from a genetic 
code reprogrammed peptide library containing trillions of unique macrocyclic 
peptides.  
    In chapter 1, I introduce the situation of infectious diseases caused by parasitic 
nematodes, such as Lymphatic filariasis and current treatment for these diseases. The 
（
）
limited effective drugs as well as increasing drug resistance call for identification of 
new drug targets and developing novel drug candidates. Subsequently, the 
characterization of cofactor-independent phosphoglycerate mutase (iPGM) is 
described and presents the potential of iPGM as a promising anti-parasite therapeutic 
target. Then, I discuss the challenges of traditional drug developing methods and 
introduce advantages of the RaPID system for peptide drug discovery.  
    In chapter 2, the development of macrocyclic peptides that bind to B. malayi 
iPGM is described as well as the determination of inhibitory activities. Several 
macrocyclic peptides are identified as B. malayi iPGM binders and exhibit inhibitory 
activity against iPGM orthologs. Furthermore, the structure activity relationship 
analysis is carried out on Bm-4 peptides by chemical modifications.  
    In chapter 3, an attempt at discovering C. elegans iPGM inhibitory peptides is 
discussed. Four macrocyclic peptides were selected and the binding affinity and 
inhibitory activity are evaluated. Ce-1 and Ce-2 are potent iPGM inhibitor with 
broad-spectrum inhibitory activity. The binding activity of Ce-2 is further studied via 
a series of chemical modification, including truncation, substitution and 
N-methylation. The binding site and inhibitory mechanism of macrocyclic peptide is 
elucidated by obtained co-crystal structure of cyclic peptide and C. elegans iPGM 
complex.   
    In the last chapter, the achievements in this study were summarized. Briefly, 
Discovery of such potent, selective, broad spectrum of macrocyclic peptide inhibitors 
gives new opportunities to develop non-druggable target against infectious nematode 
species and provide insights for rational drug design in future.	
	
	
	
	
	
	
	
	
	
	
